Carbon Dioxide (CO2) Chemosensitivity and SUDEP

Epilepsy Clinical Trial

Official title:

The Role of Central CO2 Chemosensitivity in Postictal Respiratory Depression and SUDEP

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04134754
• Other study ID #: 201908728
• Status: Recruiting
• Phase: N/A
• Start date: December 12, 2019
• Est. completion date: October 2029

Study information

• Verified date: July 2023
• Source: University of Iowa
• Contact: Study Coordinator
• Phone: 319-356-4337
• Email: dragond[@]healthcare.uiowa.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to better understand what causes Sudden Unexpected Death in Epilepsy (SUDEP). This study will enroll subjects from the University of Iowa Hospitals and Clinics (UIHC) Epilepsy Monitoring Unit (EMU) and Epilepsy Clinics. The investigators will analyze the effects of seizures on breathing, on the cardiovascular system, and on arousal. The investigators are studying these effects because some cases of SUDEP might be due, in part, to an inability to wake up or sense elevated carbon dioxide (CO2) levels when breathing is impaired. Subjects will be followed for ten years after enrollment to monitor their health.

Description:

In this study, the investigators will only enroll adults with confirmed or suspected epilepsy; there is no control group. Patients admitted to the UIHC Epilepsy Monitoring Unit (EMU) for continuous VideoEEG will undergo video recordings of their face and body, electroencephalography (EEG), and electrocardiogram (ECG) as part of their normal clinical care. Research subjects will undergo noninvasive cardiorespiratory monitoring during their EMU stay for the purpose of correlating heart rate and breathing patterns with EEG patterns related to their seizures.

Eligible subjects will undergo several respiratory tests. This may include sniffing and breath holding and breathing through tubes of different sizes. One test, called the hypercapnic ventilatory response (HCVR), will have you rebreathe a gas mixture of 6% carbon dioxide and 50% oxygen to look at how more you breath in response to the increase in carbon dioxide levels. The investigators will then measure how much more subjects breathe in response to the increase in carbon dioxide levels, and also how breathing feels at the end of the test. The investigators will analyze the relationship between the HCVR and cardiorespiratory changes from seizures. The investigators will also analyze the effect of seizures on the HCVR. The HCVR test will be done by our respiratory therapist during subjects' stay in the EMU.

Some subjects will be asked to participate in repeat testing of the HCVR 3 more times as an outpatient over the next 2 years. Additional subjects will also be enrolled from the clinic and will also undergo HCVR testing 4 times over the 2 years. All subjects will agree to undergo an interview in person or by phone, email, or questionnaire annually for ten years. They will also provide consent for follow-up with a personal contact in the event of subject death, for the purpose of ascertaining whether the death was due to SUDEP.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 335
• Est. completion date: October 2029
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

1. The subject is between 18 and 99 years of age.

2. Confirmed or suspected epilepsy.

3. Admission to the EMU for spell characterization (EMU group) or undergoing care in the University of Iowa Health Care Epilepsy Clinic.

Exclusion Criteria:

1. History of uncontrolled cardiac, pulmonary, or hepatic disease.

2. Progressive or uncontrolled neurologic disease unrelated to epilepsy.

3. Current opioid use.

4. Women of child-bearing potential who are pregnant or capable of becoming pregnant (e.g. sexual activity within the past 21 days without a highly effective form of birth control or positive urine pregnancy test).

5. Other comorbid condition that may influence the safety or feasibility of HCVR testing.

6. Limited decision-making capacity and absence of a qualified representative.

Related Conditions & MeSH terms

• Epilepsy
• SUDEP

Intervention

Other:
• 6% Carbon dioxide/50% oxygen/balance nitrogen mixture
In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you

Locations

Country	Name	City	State
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
University of Iowa

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the correlation between baseline central CO2 chemosensitivity and the increase in transcutaneous CO2 levels after a seizure.	The change in HCVR slope (change in minute ventilation [liters/min] vs change in end tidal CO2 [mm Hg]) will be correlated with the increase in transcutaneous CO2 level (mm Hg) provoked by a seizure.	Immediately before and after a seizure, variable for each subject but approximately 10 minutes
Primary	Determine the correlation between baseline central CO2 chemosensitivity and the duration of transcutaneous CO2 elevation above baseline after a seizure.	The change in HCVR slope (change in minute ventilation [liters/min] vs change in end tidal CO2 [mm Hg]) will be correlated with the duration (minutes) of end tidal CO2 elevation above pre-seizure baseline	Duration of hospital admission, approximately 5 days
Primary	Effect of seizures on HCVR slope (liters/min/mm Hg)	The percent change in HCVR slope (liters/min/mm Hg) from baseline that is induced by a seizure will be measured. The HCVR will be administered at 30 minutes, 2 hours, and 18 hours after nonconvulsive seizures. The HCVR will be administered at 2 hours and 18 hours after convulsive seizures.	Up to 18 hours after a seizure.
Primary	Determine the stability of the HCVR slope over time in patients with epilepsy. of the HCVR over time in patients with epilepsy	The stability of the HCVR slope (liters/min/mm Hg) measured 8 months for 2 years will be assessed using a generalized linear mixed model.	2 years
Secondary	Change in respiratory rate provoked by seizures	Frequency of breaths (breaths/minute) will be measured using respiratory effort belts around the chest and abdomen	Immediately before and after a seizure, variable for each subject but approximately 10 minutes